张辉,中山医医疗系八二届,和硕士研究生八八届。现任费城托马斯-杰佛逊大学医学院传染内科副教授,美东校友会理事。张辉于一九八八年来美,在纽 约州立大学上州医学中心直接攻读微生物学博士学位。九三年毕业后到杰佛逊大学医学院作博士后和研究助理。九七年被聘为tenure-track 助理教授。 2001年升为副教授至今。他的科研方向是HIV的分子生物学和抗HIV药物的开发。作为第一作者或责任作者,他已在诸多高影响的杂志,比如“自然 (Nature)” ,“新英格兰医学杂志(NEJM)” ,“美国科学院院报(PNAS)”, “生物化学杂志(JBC) ” ,“病毒学杂志(JVI) ” 上发表论文。在很多有影响的专业会议上作重点发言(keynote speech)和一般发言(talk)。作为 Principle Investigator (PI), 现有两个RO1 NIH 基金 (AI047720 和 AI058798)。作为副主编,他还参与了中国医药高校研究生教材“分子病毒学” 的编辑工作,执笔编写了“人类免疫缺陷性病毒(HIV) ” 一章。最近与母校的科研人员合作,参与了重组SARS疫苗的开发和SARS病毒的分子病理学的研究。。

Thomas Jefferson University zhang
Jefferson Medical College
Department of Medicine
Division of Infectious Diseases
Associate Professor     

Thomas Jefferson University
College of Graduate Studies
Microbiology and Molecular Virology
Ph.D Program










Mailing Address
1020 Locust Street, JAH329
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: (215) 503-0163
Hui.Zhang@jefferson.edu
http://www.tju.edu/virology/home/immunopath2.cfm
Qualifications
Ph.D., State University of New York, Health Science Center at Syracuse, Microbiology and Immunology, 1994
M.D., Sun Yatsen (Zhongshan) University, Medical School, China, 1982

专利权:Innovations


1. Zhang H and Pomerantz RJ: A method for increasing transduction efficiency of recombinant retroviral vectors. US patent No: 5,763,242.
2. Zhang H, Pomerantz RJ, and Yang, B: Multimerization of HIV-1 Vif protein as a potential anti-HIV-1 therapeutic target. US patent No: 6,653,443. International patent, pending
3. Zhang H: Method to search peptide inhibitors to block the entrance of any plant, animal, or human viruses. US patent pending.

主要著作:Publications (in English only)


1. Zhang H, Zhang Y, Spicer TP, Abbott LZ, Abbott M, Poiesz BJ. Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance. AIDS Research and Human Retroviruses. 1993. 9:1287-1296
2. Zhang H, Zhang Y, Spicer T, Henrard D, Poiesz BJ. Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle. Journal of Virology. 1995. 69: 3675-3682
3. Zhang H, Bagasra O, Niikura M, Poiesz BJ, Pomerantz RJ. Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. Journal of Virology 1994. 68: 7591-7597
4. Duan L, Zhang H, Oakes JW, Bagasra O, Pomerantz RJ. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Human Gene Therapy. 1994.
5: 1315-1324 5. Bagasra O, Seshama T, Zhang H, Bobroski L, Dornadula G, Saikumari P, Pomerantz RJ. One-step amplification of HIV-1 mRNA and at a single-cell level by in situ PCR. Cell Vision. 1995. 2: 425-429.
6. Zhang H, Duan LX, Dornadula G, Pomerantz RJ. Increasing transduction efficiency of recombinant murine retrovirus vectors by initiation of endogenous reverse transcription: potential utility for genetic therapies. Journal of Virology. 1995. 69: 3929-3932
7. Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. Journal of Virology. 1996. 70: 628-634
8. Zhang H, Dornadula G, Pomerantz RJ. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. Journal of Virology. 1996. 70: 2809-2824
9. Zhang H, Dornadula G, Alur P, Laughlin MA, Pomerantz RJ. Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. Proceedings of the National Academy of Sciences (USA). 1996. 93: 12519-1252
10. Niikura M, Dornadula G, Zhang H, Mukhtar M, Lingxun D, Khalili K, Bagasra O, Pomerantz RJ. Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell. Oncogene. 1996. 13: 313-322
11. Dornadula G, Zhang H, Bagasra O, Pomerantz RJ. Natural endogenous reverse transcription of simian immunodeficiency virus. Virology. 1997. 227: 260-267
12. Zhang H, Dornadula G, Pomerantz RJ. Natural endogenous reverse transcription of HIV type 1 (Review). AIDS Research and Human Retroviruses. 1998. 14: S93-95
13. Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, Pomerantz RJ. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. New England Journal of Medicine. 1998. 339: 1803-1809
14. Zhang H, Dornadula G, Pomerantz RJ. Natural endogenous reverse transcription of HIV-1 (Review). Journal of Reproductive Immunology. 1998. 41: 255-260.
15. Dornadula G, Zhang H, Shetty S, Pomerantz RJ. HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission. Virology. 1999. 253: 10-16
16. Kubota S, Zhang H, Kitahara S, Pomerantz RJ. Role of lentiviral lytic polypeptide I (LLP-1) in the selective cytotoxicity of g-glutamylcysteine ethyl ester against human immunodeficiency virus type 1-producing cells. Antiviral Chemistry and Chemotherapy. 1999. 10: 121-127.
17. Dornadula G, Zhang H, Van Uitert B, Stern J, Livornese L Jr, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J, Pomerantz RJ. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active antiretroviral therapy (HAART). JAMA. 1999. 282: 1627-1632.
18. Zhang H, Dornadula G, Orenstein J, Pomerantz RJ. Morphologic changes in HIV-1 virions secondary to intra-virion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. Journal of Human Virology. 2000. 3: 165-72
19. Dornadula G, Yang SC, Pomerantz RJ, Zhang H*. Partial rescue of the Vif-negative phenotype of mutant HIV-1 viruses from non-permissive cells by intravirion reverse transcription. Journal of Virology. 2000. 74: 2594-2602.
20. Zhang H*, Pomerantz RJ, Dornadula G, Sun Y. HIV-1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. Journal of Virology. 2000. 74: 8252-8261.
21. Dornadula G, Nunnari G, Vanella M, Roman JR, Babinchak T, DeSimone J, Stern J, Braffman M, Zhang H, and Pomerantz RJ. Human Immunodeficiency Virus Type 1-Infected Persons with Residual Disease and Virus Reservoirs on Suppressive Highly Active Antiretroviral Therapy Can Be Stratified into Relevant Virologic and Immunologic Subgroups. Journal of Infectious Diseases. 2001. 183: 1682-1687.
22. Pomerantz RJ and Zhang H: Residual HIV-1 Persistence during suppressive HAART (Review). Current Clinical Topics in Infectious Diseases. 2001. 21: 1-30.
23. Yang SC, Sun Y, Zhang H*. The multimerization of human immunodeficiency virus type I (HIV-1) Vif proteins: A requirement for Vif function in the viral life cycle. Journal of Biological Chemistry. 2001. 276: 4889-4893.
24. Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, and Pomerantz RJ. Residual HIV-1 disease in seminal cells of HIV-infected men on suppressive HAART: latency without on-going cellular infections. AIDS. 2001. 15: 1-7
25. Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A, Pomerantz RJ. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. Journal of Infectious Diseases. 2002. 186: 1403-1411
26. Mascio MD, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, Pomerantz RJ, Perelson AS. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 Copies per milliliter, with a half-life of 6 months. Journal of Virology. 2003. 77: 2271-2275.
27. Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H*. Potent suppression of viral infectivity by peptides that inhibit multimerization of human immunodeficiency virus type I (HIV-1) Vif proteins. Journal of Biological Chemistry. 2003. 278: 6596 - 6602
28. Zhang H*, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly-synthesized HIV-1 DNA. Nature. 2003. 424: 94-98.
29. Gallego J, Greatorex J, Zhang H, Yang B, Arunachalam S, Fang J, Seamons J, Lea S, Pomerantz R, Lever AM. Rev binds specifically to a purine loop in the SL1 region of the HIV-1 leader RNA. Journal of Biological Chemistry. In press. 2003 Jul 8 [Epub ahead of print].
30. Zhang H*. CEM15 (APOBEC3G) versus HIV-1 Vif: a story of defense and anti-defense: (Invited review). Journal of Molecular Medicine. Submitted.